The company won this accolade after having established a broad portfolio of late-stage product candidates based on specialised cells known as mesenchymal lineage adult stem cells.
Mesoblast has three cell therapy product candidates in Phase 3 clinical trials - acute graft versus host disease, chronic heart failure, and chronic lower back pain caused by disc degeneration.
The company expects the primary endpoint results from its Phase 3 trial in pediatric acute graft versus host disease in Q1 2018.
Last year, Mesoblast was granted a patent in the U.S covering the use of mesenchymal precursor cells in the treatment of rheumatic diseases, including rheumatoid arthritis.
Earlier this year, the company raised circa $51 million to fund the costs of its on-going Tier 1 clinical programs.
Frost & Sullivan’s Best Practices Awards recognise companies that lead the development and successful introduction of high-tech solutions for customers’ needs, altering the industry landscape in the process.
Its industry analyst team benchmarks market participants and measures their performance through primary interviews and secondary industry research to evaluate and identify best practices.